MARKET

AERI

AERI

Aerie Pharmaceut
NASDAQ
15.11
-0.02
-0.10%
Opening 12:29 09/29 EDT
OPEN
15.14
PREV CLOSE
15.12
HIGH
15.14
LOW
15.09
VOLUME
570.46K
TURNOVER
3.50M
52 WEEK HIGH
15.37
52 WEEK LOW
4.810
MARKET CAP
746.38M
P/E (TTM)
-14.4698
1D
5D
1M
3M
1Y
5Y
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
Zacks · 14h ago
EXCLUSIVE: Wondermind and Aerie Partner to Launch Content Series
The "Mind, Body, Real Talk" series and event will include an exclusive interview with Aly Raisman.
WWD · 1d ago
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
Zacks · 09/20 16:04
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
DURHAM, N.C., September 13, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Lead...
Business Wire · 09/13 12:00
Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection
Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.
Zacks · 09/12 15:26
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
Zacks · 09/08 16:58
Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/07 15:30
Hedge Funds Were Right About These 10 Small-Cap Stocks
In this article, we will discuss how hedge funds were right about these 10 small-cap stocks. To skip our detailed analysis of well-performing industries in 2022, go directly and see Hedge Funds Were Right About These 5 Small-Cap Stocks. With the threat of ...
Insider Monkey · 09/02 15:19
More
About AERI
Aerie Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The Company's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AERI stock methods without spending real money on the virtual paper trading platform.